British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Trump has claimed the company delayed an announcement for its vaccine until after the 2020 presidential election.

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Pfizer shares are trading lower Wednesday after a Wall Street Journal report revealed that U.S. prosecutors are investigating ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

The blood thinner generated revenue for Pfizer of nearly $7.4 billion last year. It loses patent exclusivity in the U.S. in 2027. The company's fourth-highest moneymaker in its Vyndaqel franchise ...